Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study

Multicenter LYSA study of interim ctDNA assessment in primary mediastinal large B-cell lymphoma. MRD detection after frontline therapy strongly complemented PET response criteria in predicting outcome. Level 2.

Blood AdvPubMed 41979332